XellSmart Achieves Fourth Consecutive Regulatory Approval for Breakthrough Cell Therapy for MSA-P XellSmart secures its fourth consecutive IND clearance from the US FDA and China's NMPA for a new cell therapy targeting MSA-P, showcasing its innovative approach.

XellSmart Achieves Fourth Consecutive Regulatory Approval for Breakthrough Cell Therapy for MSA-P #China #Suzhou #XellSmart #iPSC_therapy #MSA-P

XellSmart Achieves FDA Clearance for Innovative Cell Therapies Addressing Major CNS Disorders XellSmart Biomedical has received FDA clearance for three groundbreaking allogeneic iPSC-derived cell therapies aimed at treating Parkinson's disease, spinal cord injuries, and ALS, marking a significant advancement in biomedicine.

XellSmart Achieves FDA Clearance for Innovative Cell Therapies Addressing Major CNS Disorders #China #Suzhou #Parkinson's_Disease #ALS #XellSmart

XellSmart's Breakthrough Spinocord Injury Therapy Achieves FDA Approval for Clinical Trials XellSmart's innovative allogeneic iPSC-derived cell therapy has received FDA approval for clinical trials, offering hope for spinal cord injury treatment.

XellSmart's Breakthrough Spinocord Injury Therapy Achieves FDA Approval for Clinical Trials #China #Suzhou #Spinal_Cord_Injury #XellSmart #iPSC_therapy

XellSmart's Breakthrough Therapies for Parkinson's and ALS Approved by FDA for Clinical Trials XellSmart Biopharmaceutical has achieved FDA approval for its innovative cell therapies aimed at treating Parkinson's Disease and ALS, moving towards clinical trials.

XellSmart's Breakthrough Therapies for Parkinson's and ALS Approved by FDA for Clinical Trials #Parkinson's_Disease #ALS #XellSmart